ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers(AbbVie (United States)), Joel D. Leverson(AbbVie (United States)), Erwin R. Boghaert(AbbVie (United States)), Scott Ackler(AbbVie (United States)), Nathaniel D. Catron(AbbVie (United States)), Jun Chen(AbbVie (United States)), Brian D. Dayton(AbbVie (United States)), Hong Ding(AbbVie (United States)), Sari H. Enschede(AbbVie (United States)), Wayne J. Fairbrother, David C.S. Huang(The University of Melbourne), S.G. Hymowitz, Sha Jin(AbbVie (United States)), Seong Lin Khaw(The University of Melbourne), Peter Kovar(AbbVie (United States)), Lloyd T. Lam(AbbVie (United States)), Jackie Lee, Heather Maecker, Kennan C. Marsh(AbbVie (United States)), Kylie D. Mason(The Royal Melbourne Hospital), Michael J. Mitten(AbbVie (United States)), Paul Nimmer(AbbVie (United States)), Anatol Oleksijew(AbbVie (United States)), Chang H. Park(AbbVie (United States)), Cheol‐Min Park(AbbVie (United States)), Darren C. Phillips(AbbVie (United States)), Andrew W. Roberts(The Royal Melbourne Hospital), Deepak Sampath, John F. Seymour(The University of Melbourne), Morey L. Smith(AbbVie (United States)), Gerard M. Sullivan(AbbVie (United States)), Stephen K. Tahir(AbbVie (United States)), Chris Tse(AbbVie (United States)), Michael Wendt(AbbVie (United States)), Xiao Yu(AbbVie (United States)), John Xue(AbbVie (United States)), Haichao Zhang(AbbVie (United States)), Rod Humerickhouse(AbbVie (United States)), Saul H. Rosenberg(AbbVie (United States)), Steven W. Elmore(AbbVie (United States))
Cited by 3,011
Abstract
Related Papers
<i>miR-15</i> and <i>miR-16</i> induce apoptosis by targeting BCL2
Amelia Cimmino, George A. Calin, Muller Fabbri et al.|Proceedings of the National Academy of Sciences|2005|3.5k